Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01859988 · ClinicalTrials.gov registry record · Phase 2

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
380
Enrollment target
20
Study locations

NCT01859988 is a Phase 2 study of Atopic Dermatitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 380 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01859988, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Placebo
  • DRUG Dupilumab

Study Locations (20)

California

  • - Bakersfield
  • - San Diego
  • - Santa Monica

Alabama

  • - Birmingham
  • - Mobile

Florida

  • - Jacksonville
  • - Ormond Beach

Massachusetts

  • - Andover
  • - Boston

New York

  • - New York
  • - Rochester

Arizona

  • - Tucson

Illinois

  • - Skokie

Louisiana

  • - New Orleans

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2013-05
Est. Completion 2014-09
Phase Phase 2

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01859988

The ClinicalTrials.gov registry entry for NCT01859988 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (37% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01859988 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT01859988 about?

NCT01859988 is a clinical study titled "Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis". To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

What is the current status of trial NCT01859988?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2013-05. Estimated completion is 2014-09.

What conditions does trial NCT01859988 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT01859988?

The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).

Who is sponsoring clinical trial NCT01859988?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01859988 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.